You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

CLINICAL TRIALS PROFILE FOR ATROPINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Atropine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000170 ↗ Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia Completed National Eye Institute (NEI) Phase 3 1999-04-01 - To determine whether the success rate with drug treatment (atropine) of amblyopia due to strabismus or anisometropia in patients less than 7 years old is equivalent to the success rate with occlusion (patching) therapy - To develop more precise estimates of the success rates of amblyopia treatment - To identify factors that may be associated with successful treatment of amblyopia - To collect data on the course of treated amblyopia to provide more precise estimates of treatment effects than are now available Extended Follow up of Study Patients - Primary: To determine the long-term visual acuity outcome at age 10 years and at age 15 years in patients diagnosed with amblyopia before age 7 years. - Secondary: To determine whether the long-term visual acuity outcome at age 10 years and at age 15 years differs between patients who received patching followed by best clinical care and patients who received atropine followed by best clinical care
NCT00000170 ↗ Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia Completed Jaeb Center for Health Research Phase 3 1999-04-01 - To determine whether the success rate with drug treatment (atropine) of amblyopia due to strabismus or anisometropia in patients less than 7 years old is equivalent to the success rate with occlusion (patching) therapy - To develop more precise estimates of the success rates of amblyopia treatment - To identify factors that may be associated with successful treatment of amblyopia - To collect data on the course of treated amblyopia to provide more precise estimates of treatment effects than are now available Extended Follow up of Study Patients - Primary: To determine the long-term visual acuity outcome at age 10 years and at age 15 years in patients diagnosed with amblyopia before age 7 years. - Secondary: To determine whether the long-term visual acuity outcome at age 10 years and at age 15 years differs between patients who received patching followed by best clinical care and patients who received atropine followed by best clinical care
NCT00000333 ↗ Evaluation of Benztropine for Cocaine Craving - 2 Completed Washington D.C. Veterans Affairs Medical Center Phase 2 2001-05-01 The purpose of this study is to compare the efficacy of benztropine (or DA reuptake inhibitor) with atropine and placebo in affecting stimulated craving to cocaine cues.
NCT00000333 ↗ Evaluation of Benztropine for Cocaine Craving - 2 Completed National Institute on Drug Abuse (NIDA) Phase 2 2001-05-01 The purpose of this study is to compare the efficacy of benztropine (or DA reuptake inhibitor) with atropine and placebo in affecting stimulated craving to cocaine cues.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Atropine

Condition Name

Condition Name for Atropine
Intervention Trials
Myopia 33
Anesthesia 27
Postoperative Pain 21
Hypotension 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Atropine
Intervention Trials
Myopia 44
Pain, Postoperative 38
Hypotension 34
Vomiting 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Atropine

Trials by Country

Trials by Country for Atropine
Location Trials
Egypt 108
United States 93
China 28
Turkey 25
Korea, Republic of 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Atropine
Location Trials
Texas 10
California 10
Maryland 9
New York 7
Ohio 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Atropine

Clinical Trial Phase

Clinical Trial Phase for Atropine
Clinical Trial Phase Trials
Phase 4 137
Phase 3 47
Phase 2/Phase 3 16
[disabled in preview] 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Atropine
Clinical Trial Phase Trials
Completed 204
Recruiting 76
Not yet recruiting 59
[disabled in preview] 47
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Atropine

Sponsor Name

Sponsor Name for Atropine
Sponsor Trials
Assiut University 16
Mansoura University 14
Ain Shams University 14
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Atropine
Sponsor Trials
Other 508
Industry 27
NIH 16
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.